Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell cycle protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    279 result(s) found for: Cell cycle protein. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-000650-11 Sponsor Protocol Number: HEP002 Start Date*: 2014-09-15
    Sponsor Name:Promethera Biosciences
    Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients.
    Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003213-18 Sponsor Protocol Number: RHMCAN1129 Start Date*: 2017-01-13
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A Phase Ib/II combination trial of acalabrutinib with rituximab, cyclophosphamide, doxorubicin,vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
    Medical condition: Diffuse large B-cell lymphomas (most common type of non-Hodgkins lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003715-38 Sponsor Protocol Number: D4190C00006 Start Date*: 2016-05-12
    Sponsor Name:MedImmune LLC
    Full Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer
    Medical condition: Locally advanced or metastatic squamous or nonsquamous non- small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000665-36 Sponsor Protocol Number: 20180015 Start Date*: 2019-06-12
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) NL (Completed) ES (Ongoing) CZ (Completed) FR (Completed) BG (Completed) SK (Completed) FI (Completed) LT (Completed) AT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-005520-16 Sponsor Protocol Number: BO20603 Start Date*: 2007-05-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Ensayo clínico de fase III multicéntrico, randomizado, doble ciego, controlado con placebo, para comparar la eficacia de bevacizumab en combinación con rituximab y CHOP (RA CHOP) frente a rituxima...
    Medical condition: Pacientes con linfoma difuso de células B grandes (LDCBG) CD20-positivo no tratados previamente, que presentan enfermedad de riesgo intermedio-bajo, intermedio-alto o alto, de acuerdo con el índic...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) FR (Completed) CZ (Completed) GR (Completed) PT (Completed) GB (Completed) SE (Completed) DE (Completed) IT (Completed) PL (Completed) SK (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-002444-40 Sponsor Protocol Number: EMC-MM-KPT-330-001 Start Date*: 2014-10-16
    Sponsor Name:Erasmus MC
    Full Title: A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.
    Medical condition: A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023772-71 Sponsor Protocol Number: C16006 Start Date*: 2011-06-07
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Predni...
    Medical condition: mieloma múltiple de nuevo diagnóstico
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004568-72 Sponsor Protocol Number: ASTX029-01 Start Date*: 2021-05-27
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10053571 Melanoma LLT
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002354-12 Sponsor Protocol Number: CMBG453X2101 Start Date*: 2016-02-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004977-23 Sponsor Protocol Number: DP312804 Start Date*: 2013-04-25
    Sponsor Name:SFJ LungCancer, Ltd.
    Full Title: ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF 00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL CELL...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005819-26 Sponsor Protocol Number: 26866138-MMY-2036 Start Date*: 2006-05-19
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    10028228
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PT (Completed) ES (Completed) IT (Completed) GR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003436-13 Sponsor Protocol Number: 105RC101 Start Date*: 2016-05-24
    Sponsor Name:TRACON Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Prematurely Ended) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-006052-14 Sponsor Protocol Number: C1071007 Start Date*: 2022-05-04
    Sponsor Name:PFIZER INC
    Full Title: A randomized, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing auto...
    Medical condition: MULTIPLE MYELOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Ongoing) AT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005141-32 Sponsor Protocol Number: MYL-1402O-3001 Start Date*: 2016-07-11
    Sponsor Name:Mylan GmbH
    Full Title: Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous...
    Medical condition: Stage IV unresectable, recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) HR (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003094-18 Sponsor Protocol Number: KCP-330-012 Start Date*: 2017-06-12
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients with Multiple Myeloma Previously Treated with Lenalidomide, Pomalidomide, Bortezomib, Ca...
    Medical condition: Refractory multiple myeloma (RMM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005046-23 Sponsor Protocol Number: POL 2 Start Date*: 2009-03-23
    Sponsor Name:Polyphor AG
    Full Title: A Phase IIa, Proof of Concept Study to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients with Multiple Myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2017-000830-68 Sponsor Protocol Number: BO39813 Start Date*: 2018-03-19
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Medical condition: Multiple Myeloma (MM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) SE (Completed) DE (Completed) CZ (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021111-17 Sponsor Protocol Number: IST-CAR-506 Start Date*: 2011-05-16
    Sponsor Name:HOVON Foundation
    Full Title: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Medical condition: newly diagnosed multiple myeloma patients
    Disease: Version SOC Term Classification Code Term Level
    13.1 10005329 - Blood and lymphatic system disorders 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006123-13 Sponsor Protocol Number: MM-07-07 Start Date*: 2008-01-11
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: A MULTICENTER, OPEN LABEL STUDY OF VELCADE, MELPHALAN AND PREDNISONE (VMP) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Medical condition: Treatment of patients with relapsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004425-23 Sponsor Protocol Number: OMC02/20 Start Date*: 2021-01-28
    Sponsor Name:Oslo University Hospital, Department of Hematology
    Full Title: A Phase 2, single arm, open label, multicenter study to assess minimal residual disease after isatuximab in combination with bortezomib and lenalidomide with minimal dexamethasone in patients with ...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 19:36:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA